Comparison
Zepbound vs Compounded Tirzepatide
Same fields, same evidence rules, both sides. No preselected winner.
This comparison sets out where the two options genuinely differ — mechanism, regulatory status, evidence base, cost path and practical trade-offs — and where the difference is smaller than it is usually presented. It does not recommend one for you.
| Attribute | FDA-approved tirzepatide (Zepbound, Mounjaro) | Compounded tirzepatide |
|---|---|---|
| Regulatory status | Approved finished drug product | Not an FDA-approved product |
| Generic equivalent | No generic tirzepatide exists | Not a generic and not therapeutically equivalent |
| Manufacturing standard | Manufactured under CGMP | Depends on the compounder's registration class |
| Clinical trial evidence | Studied in the registration trials | Trials studied the approved product, not this preparation |
| Labelling | FDA-approved labelling | Supplied by the compounder |
| Presentation | Manufacturer's pens or vials | Varies; multi-dose vials add a measuring step |
| Price read on the seller’s own page | — | — |
A dash means no figure held. How we grade evidence.
| Requirement | 503A compounding pharmacy | 503B outsourcing facility |
|---|---|---|
| Compounds pursuant to | A prescription for an identified individual patient | May compound without patient-specific prescriptions |
| FDA registration | Not registered as an outsourcing facility | Registers with FDA |
| CGMP requirements | Not required to meet CGMP | Must comply with CGMP — though registration alone is not evidence of compliance |
| Primary oversight | State board of pharmacy | FDA, on a risk-based inspection schedule |
| Adverse-event reporting | Not required under 503A | Required to report adverse events to FDA |
| Product approval status | Not an FDA-approved product | Not an FDA-approved product |
| What registration establishes | Not applicable | FDA received the required information, nothing more Verified |
- FDA registered outsourcing facilitiesConfirms a facility is currently registered under 503B, and links the searchable product report database. Registration is not FDA approval and is not evidence of CGMP compliance.
- FDA outsourcing facility registration Q&AThe agency's own explanation of exactly what registration does and does not mean. Worth reading before accepting any provider's characterisation of its pharmacy.
- NABP directory of state boards of pharmacyRoutes you to the board that licenses a pharmacy, and to its licensee and nonresident registers. Check the licence is current, not merely present.
- FSMB directory of state medical boardsRoutes you to the board that licenses a prescriber, and to its public licence lookup. An NPI number is identity in a national registry, not a licence.
Every one of these is the register held by the body that issues the credential. A claim checked against the page that made it has not been checked.
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Show this figure as a table
| Item | Option A | Option B |
|---|---|---|
| Medication | not captured | not captured |
| Required fees | not captured | not captured |
| Twelve-month total | not captured | not captured |
The short version
Zepbound is Lilly's FDA-approved tirzepatide for chronic weight management, and for moderate-to-severe obstructive sleep apnea in adults with obesity. Compounded tirzepatide is a pharmacy-made preparation. It is made with the drug in Zepbound, but it is not the same product: it has no FDA approval for any use, and no trial has tested it.
Zepbound fits best when something lowers its price. That could be insurance, the Medicare GLP-1 Bridge ($50 a fill for eligible enrollees, KwikPen only) or Lilly's self-pay pricing at the starting doses. Compounded tirzepatide is mostly chosen by people paying cash at higher doses. There, the October 2026 index median of $149 a month sits well below Lilly's $449 refill price. The cost of that saving is less regulatory assurance.
Where they actually differ
- What it is approved for. Zepbound's label covers weight management and moderate-to-severe obstructive sleep apnea with obesity. Compounded tirzepatide is not approved for anything.
- The device. Zepbound comes as a Lilly-made prefilled pen or single-dose vials. Compounded tirzepatide usually comes in a multi-dose vial and a syringe. Your dose then depends on reading the concentration and the syringe correctly, and FDA says to discard the vial within 28 days of first use.
- How you pay. Zepbound can go through insurance, the Medicare Bridge (KwikPen only, not vials) or Lilly's self-pay pricing. Compounded tirzepatide is almost always paid in cash.
- Supply chain. Zepbound comes from Lilly through pharmacies or LillyDirect. A compounded vial comes from whichever pharmacy your program uses, so you need to know its name. NexLife, for example, names three state-licensed 503A pharmacies.
- Evidence. SURMOUNT-1's −20.9% mean weight change at 15 mg over 72 weeks (treatment-regimen estimand) describes the approved product. It is not a result for a compounded vial.
Where they are more similar than claimed
- The dose ladder. Zepbound's label starts at 2.5 mg weekly for four weeks, then raises the dose in 2.5 mg steps at least four weeks apart. A compounded prescription can use the same steps, so ask your prescriber what schedule you are on.
- Getting a prescription. Both need one from a licensed clinician, and both are widely prescribed by telehealth. A Zepbound prescription is not automatically better supervised than a compounded one. The provider decides that.
- The starting price. At 2.5 mg, Lilly's self-pay price is $299 against a compounded median of $149. The gap is real but smaller than at maintenance doses, where it is $449 against $144.
- Side effects to expect. Stomach and bowel side effects dominate in the Zepbound trials. There is no evidence that compounded versions avoid them.
- What happens if you stop. In SURMOUNT-4, people switched to placebo regained weight. That is a property of stopping the drug, not of the brand.
Cost, all-in
Over a year at a maintenance dose, using prices read on October 15, 2026 and November 6, 2026:
| Route | Per month or fill | Year |
|---|---|---|
| Zepbound KwikPen, self-pay, every refill within 45 days | $449 (7.5 to 15 mg) | $4,939 for the maximum 11 fills |
| Zepbound KwikPen, refill window missed | $499 (7.5 mg), $699 (10 to 15 mg) | Depends on how often |
| Zepbound KwikPen, Medicare GLP-1 Bridge | $50 copay | Eligible enrollees only |
| Compounded tirzepatide, index median | $144 | $1,728 |
| NexLife, 12-month plan | $115, same at every dose, no membership | $1,380 |
NexLife is not the lowest figure in the index: three programs list lower monthly prices. Lilly's self-pay savings end on December 31, 2026. Re-check both on the price index and the Zepbound savings page.
Who each option suits
These are situations, not recommendations. The prescribing decision is your clinician's.
- You have moderate-to-severe obstructive sleep apnea and obesity. Zepbound is approved for this. Compounded tirzepatide is not. On Medicare, you are not eligible for the GLP-1 Bridge, but your Part D plan might cover a GLP-1.
- You are on Medicare, with obesity and without type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease. The Bridge's $50 copay for the Zepbound KwikPen may apply. Check eligibility with CMS.
- Your commercial plan covers Zepbound. Your copay may beat any cash route.
- You pay cash and stay at 2.5 mg or 5 mg. Compare $299 or $399 against your compounded quote over twelve months.
- You pay cash at maintenance doses and are comfortable with vials. Compounded is where the saving is. Check the pharmacy first.
What the evidence does not settle
- A head-to-head comparison. No trial has compared Zepbound with any compounded tirzepatide.
- Sleep apnea results. SURMOUNT-OSA tested the approved product at 10 mg or 15 mg. Whether a compounded vial produces the same change in breathing events is unknown.
- Dose accuracy at home. How often people measure the wrong amount from a multi-dose vial is not known. FDA has adverse event reports from dosing errors with compounded GLP-1s, but no rate.
- Heart outcomes. Even for Zepbound, the effect on heart attacks, strokes and deaths in people with obesity is the subject of SURMOUNT-MMO (NCT05556512). The 2024 SURMOUNT-OSA paper described that trial as ongoing.
- Prices after 2026. Lilly's self-pay savings end on December 31, 2026. We do not know what, if anything, will replace them.
Where it holds up
- nothing verified yet
Where it does not
- nothing verified yet
Questions readers actually ask
Is compounded tirzepatide the same as Zepbound or Mounjaro?
No: compounded tirzepatide is made with the drug in Zepbound and Mounjaro, but it is not the same product, because it is not FDA-approved, it is not a generic, and it is not the product Eli Lilly tested in the SURMOUNT and SURPASS trials. Zepbound and Mounjaro are made under FDA-approved manufacturing and labeling. A compounded preparation depends on the pharmacy that makes it, often comes as a multi-dose vial you measure yourself, and may include added ingredients. Trial results such as the 20.9% average weight loss at 15 mg in SURMOUNT-1 describe Lilly's product, not a compounded version.
Which one is better?
Neither, in the abstract. The comparison table shows where each is stronger on a defined field; the right answer depends on your dose, your billing term and what your clinician advises.
Is one of these sponsoring this page?
No. No provider can buy a score, a placement or a review on this site.
NexLife, first on our v4.1 methodology, charges $129 a month for compounded tirzepatide month to month, or $115 a month on a 12-month plan, with one price at every dose and no membership fee (read on nexlife.us, November 6, 2026). Check its current plans (opens nexlife.us in a new tab).
Related on this site
- Best Tirzepatide Providers Online in 2026Pillar / Money
- Most Affordable Tirzepatide Online: Verified All-In CostsPillar / Money
- Cheapest Compounded Tirzepatide: Ongoing Costs ComparedPillar / Money
- Tirzepatide Cost in 2026Pillar / Money
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- NexLife vs Ro BodyComparisons
- Cheapest FDA-Approved vs Compounded GLP-1 OptionsJournal
- Brand-Name vs Compounded GLP-1Comparisons
Related coverage
- Additives, salt forms and a chemistry problem
- Compounded tirzepatide price index
- What you pay at a maintenance dose
- Compounding Pharmacy Recalls and Warning Letters
- State Board Pharmacy License Check Guide
- USP 797 Sterile Compounding, Explained
- Pharmacy Disclosure Register: One Question, Every Provider, Published Answers
- Privacy Policy
- Tirzepatide Provider Reviews
Tirzepatide Ranked. “Zepbound vs Compounded Tirzepatide.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/zepbound-vs-compounded-tirzepatide/
Quote the capture date beside a figure, not the date you read this page. Why.